Management of Resectable Pancreatic Cancer

Video

This video examines the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.

In this video, Davendra Sohal, MD, MPH, of the Cleveland Clinic in Cleveland, Ohio, discusses the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.

Sohal spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Related Content
Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer

Ariana Pelosci
November 21st 2024
Article

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Managing Pancreatic Cancer Through Risk Factors, Diagnosis, and AEs

Managing Pancreatic Cancer Through Risk Factors, Diagnosis, and AEs

Tim Cortese
November 18th 2024
Article

A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Advancing Pancreatic Cancer Care Through Intraoperative Radiation Therapy

Kamran Idrees, MD, MSCI, MMHC, FACS ;Natalie A. Lockney, MD;Milad Baradaran, PhD, DABR
August 5th 2024
Podcast

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

Mitazalimab Combo Yields Meaningful Survival Benefit in Metastatic PDAC

Russ Conroy
November 7th 2024
Article

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.

FDA Extends Review Period for Zenocutuzumab in NRG1+ PDAC, NSCLC

Russ Conroy
November 5th 2024
Article

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.